1166227-08-2,
A66,
CHEMBL3218581,
A-66,
(2S)-N1-[2-(tert-Butyl)-4'-methyl[4,5'-bithiazol]-2'-yl]-1,2-pyrrolidinedicarboxamide,
J-501023,
C17H23N5O2S2,
MLS006010983,
SCHEMBL14833311,
CHEBI:91449,
AOB2329,
DTXSID80655299,
BCPP000449,
(2S)-1-N-[5-(2-tert-butyl-1,3-thiazol-4-yl)-4-methyl-1,3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamide,
BCP03474,
EX-A1124,
KS-00001D5K,
BDBM50042922,
s2636,
ZINC43206649,
AKOS025293511,
BCP9000211,
CS-0477,
RL00633,
SB19247,
A66, >=98% (HPLC),
BC261901,
HY-13261,
SMR004702785,
BCP0726000206,
A 66; A-66,
SW218196-2,
X7447,
W-5907,
1166227-08-2;A 66, A-66,
(2S)-N1-(5-(2-tert-butylthiazol-4-yl)-4-methylthiazol-2-yl)pyrrolidine-1,2-dicarboxamide,
(S)-N1-(2-(tert-butyl)-4'-methyl-[4,5'-bithiazol]-2'-yl)pyrrolidine-1,2-dicarboxamide,
(S)-N1-(2-tert-butyl-4'-methyl-4,5'-bithiazol-2'-yl)pyrrolidine-1,2-dicarboxamide,
(2S)-N~1~-(2-tert-Butyl-4'-methyl[4,5'-bi-1,3-thiazol]-2'-yl)pyrrolidine-1,2-dicarboxamide,
(2S)-N1-[2-(1,1-Dimethylethyl)-4'-methyl[4,5'-bithiazol]-2'-yl]-1,2-pyrrolidinedicarboxamide,
1,2-Pyrrolidinedicarboxamide, N1-[2-(1,1-dimethylethyl)-4'-methyl[4,5'-bithiazol]-2'-yl]-, (2S)-,
cc-500,
A 66,
HBPXWEPKNBHKAX-NSHDSACASA-N,
A8354,
A11202,
A66, 98%, a potent and specific p110alpha inhibitor - 100MG 100mg,